CeriBell (NASDAQ:CBLL – Get Free Report) announced its quarterly earnings results on Tuesday. The company reported ($1.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($1.03), Zacks reports. The firm had revenue of $17.20 million during the quarter, compared to the consensus estimate of $17.06 million.
CeriBell Price Performance
Shares of NASDAQ CBLL traded up $0.42 during mid-day trading on Thursday, hitting $28.30. 27,445 shares of the stock traded hands, compared to its average volume of 228,094. CeriBell has a twelve month low of $23.00 and a twelve month high of $29.53.
Wall Street Analysts Forecast Growth
CBLL has been the subject of several recent analyst reports. William Blair started coverage on shares of CeriBell in a research note on Tuesday, November 5th. They issued an “outperform” rating for the company. Canaccord Genuity Group lifted their price objective on shares of CeriBell from $30.00 to $31.00 and gave the company a “buy” rating in a report on Wednesday. JPMorgan Chase & Co. began coverage on shares of CeriBell in a research report on Tuesday, November 5th. They set an “overweight” rating and a $32.00 price target on the stock. Bank of America assumed coverage on CeriBell in a report on Tuesday, November 5th. They set a “buy” rating and a $32.00 target price on the stock. Finally, Canaccord Genuity Group started coverage on CeriBell in a research note on Tuesday, November 5th. They set a “buy” rating and a $30.00 price objective on the stock. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $31.20.
CeriBell Company Profile
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
See Also
- Five stocks we like better than CeriBell
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick
- Do ETFs Pay Dividends? What You Need to Know
- Mouse Rising: The Iger Investment Pays Off for Disney Investors
- Buy P&G Now, Before It Sets A New All-Time High
- Can CAVA Stock Be the Next Chipotle? Earnings Can Help
Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.
